Enua Pharmaceuticals (002262.SZ): Dexmedetomidine Hydrochloride Injection passes the generic drug consistency evaluation.

Zhtng Cijng APP xn, nhu Yoy (002262.SZ) fb gnggo, gngs y jnr shudo guji yopn jind gunl j hk qinf de guny ynshu du sh p ln zhsh y de "yopn bzhng shnqng pzhn tngzhsh", pzhn gi yopn tnggu fngzh yo zhling h lioxio yzhxng pngji (jinchng "yzhxng pngji"). Gi yopn yngy hx shuilu, cc tnggu yzhxng pngji jing yul y tshng shchng jngzhngl, du gngs wili de jngyng yj chnshng jj de yngxing. Zhtng Cijng APP News, Enhua Pharmaceutical (002262.SZ) announced that the company recently received the "Drug Supplementary Application Approval Notice" issued by the National Medical Products Administration regarding the Hydrochloric Acid Dorsapin Injection, approving the drug through generic drug quality and efficacy consistency evaluation (referred to as "consistency evaluation"). This drug is used for respiratory failure. This approval through consistency evaluation will help improve market competitiveness and have a positive impact on the company's future business performance.